Practical Considerations for Integrating Biosimilars Into Clinical Practice

The development of innovator biologics and now their biosimilars has created some unique challenges in oncology practice. The oncology advanced practitioner (OAP) must understand the key differences between the innovator biologic and biosimilars in regard to efficacy, safety, and immunogenicity. In...

Descripción completa

Detalles Bibliográficos
Autores principales: May, Megan B., TAUCHER, Kate Deen, Vogel, Wendy H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Practice Matters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163250/
https://www.ncbi.nlm.nih.gov/pubmed/34123479
http://dx.doi.org/10.6004/jadpro.2021.12.4.7
_version_ 1783700870793265152
author May, Megan B.
TAUCHER, Kate Deen
Vogel, Wendy H.
author_facet May, Megan B.
TAUCHER, Kate Deen
Vogel, Wendy H.
author_sort May, Megan B.
collection PubMed
description The development of innovator biologics and now their biosimilars has created some unique challenges in oncology practice. The oncology advanced practitioner (OAP) must understand the key differences between the innovator biologic and biosimilars in regard to efficacy, safety, and immunogenicity. In addition, the OAP must be able to evaluate and successfully navigate factors that may affect the adoption of biosimilars, such as the perceived cost-benefit and clinician and patient acceptance.
format Online
Article
Text
id pubmed-8163250
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-81632502021-06-10 Practical Considerations for Integrating Biosimilars Into Clinical Practice May, Megan B. TAUCHER, Kate Deen Vogel, Wendy H. J Adv Pract Oncol Practice Matters The development of innovator biologics and now their biosimilars has created some unique challenges in oncology practice. The oncology advanced practitioner (OAP) must understand the key differences between the innovator biologic and biosimilars in regard to efficacy, safety, and immunogenicity. In addition, the OAP must be able to evaluate and successfully navigate factors that may affect the adoption of biosimilars, such as the perceived cost-benefit and clinician and patient acceptance. Harborside Press LLC 2021-05 2021-05-01 /pmc/articles/PMC8163250/ /pubmed/34123479 http://dx.doi.org/10.6004/jadpro.2021.12.4.7 Text en © 2021 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Practice Matters
May, Megan B.
TAUCHER, Kate Deen
Vogel, Wendy H.
Practical Considerations for Integrating Biosimilars Into Clinical Practice
title Practical Considerations for Integrating Biosimilars Into Clinical Practice
title_full Practical Considerations for Integrating Biosimilars Into Clinical Practice
title_fullStr Practical Considerations for Integrating Biosimilars Into Clinical Practice
title_full_unstemmed Practical Considerations for Integrating Biosimilars Into Clinical Practice
title_short Practical Considerations for Integrating Biosimilars Into Clinical Practice
title_sort practical considerations for integrating biosimilars into clinical practice
topic Practice Matters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163250/
https://www.ncbi.nlm.nih.gov/pubmed/34123479
http://dx.doi.org/10.6004/jadpro.2021.12.4.7
work_keys_str_mv AT maymeganb practicalconsiderationsforintegratingbiosimilarsintoclinicalpractice
AT taucherkatedeen practicalconsiderationsforintegratingbiosimilarsintoclinicalpractice
AT vogelwendyh practicalconsiderationsforintegratingbiosimilarsintoclinicalpractice

Ejemplares similares